Current progress toward vaccines against *Toxoplasma gondii*

João Luis Garcia¹
Elisabeth A Innes²
Frank Katzer²

¹Department of Preventative Veterinary Medicine, Center of Agricultural Science, State University of Londrina, Parana, Brazil; ²Moredun Research Institute, Pentlands Science Park, Edinburgh, Scotland

Abstract: *Toxoplasma gondii* is an intracellular protozoan parasite that can infect many warm-blooded animal species and humans. Despite substantial knowledge of the biology, epidemiology, and host-pathogen interactions of *T. gondii*, there are still very few effective control strategies to prevent oocyst shedding in cats, tissue cysts in livestock for consumption, and infection and disease in humans. This article reviews current progress and targets for vaccination against *T. gondii*.

Keywords: toxoplasmosis, vaccination, livestock animals, cats, immune response, organelles

Introduction

Toxoplasma gondii is a protozoan parasite with a worldwide distribution,¹ and may be found in animals from the arctic,² rain forest,³ and arid zones,⁴ and even in marine mammals.⁵ *T. gondii* normally causes a subclinical infection in most animal species; however, a primary infection during pregnancy can cause fetal pathology, as well as abortion in humans and some animal species.^{6,7} When the human fetus is infected, it may present with hydrocephalus, chorioretinitis, deafness, and impaired mental development.⁸ The incidence of congenital toxoplasmosis in humans is highly variable across different countries/regions.⁹ The recorded incidence is usually lower in Europe and North America (six cases per 1,000 live births),^{10,11} when compared with Brazil, where cases range from 0 to 77 per 1,000 live births depending on the level of poverty in the region studied.⁷ A study in Brazil reported detection of parasitemia and isolation of *T. gondii* from peripheral blood in 15.2% of children with congenital toxoplasmosis, which is an excessively large number considering the difficulty of detecting the parasite in blood.¹²

Additionally, in spite of highly effective antiretroviral therapy, the estimated incidence of toxoplasmic encephalitis is 15.9% in patients infected with the human immunodeficiency virus.¹³ Before highly effective antiretroviral therapy, encephalitis caused by *T. gondii* was the most frequent opportunistic infection complicating acquired immunodeficiency syndrome.¹⁴ Ocular toxoplasmosis is another concern with *T. gondii* infection, and may occur following congenital and acquired transmission;¹⁵ the risk of ocular toxoplasmosis is highly variable depending on geographic region, ranging from 2% in Europe and North America to 18% in southern Brazil.

Moreover, there are reports that *T. gondii* may be associated with psychiatric disorders,¹⁶ and may affect human behavior, personality, and other phenotypic traits. This parasite may change the behavioral phenotype of the host (mouse) to increase its likelihood of transmission to a new host (cat) by predation.¹⁷

Correspondence: João Luis Garcia
Departamento de Medicina Veterinária Preventiva, Centro de Ciências Agrárias, Universidade Estadual de Londrina, CP 6001, CEP 86051-990, Londrina-PR, Brazil
Email: jlgarcia@uel.br

The main infection sources for humans are consumption of vegetables or water contaminated with sporulated *T. gondii* oocysts and undercooked meat infected with tissue cysts. The risk of becoming infected depends on culinary practices, such as regular consumption of raw or undercooked meat and living in an environment with a higher risk of oocyst contamination. Those relative risks have been shown in research isolating *T. gondii* from meat and the environment.^{18–21} Hill et al²² recently suggested that cats were an important source of *T. gondii* infection in the USA, based on finding a low frequency of *T. gondii* in meat samples.²³ In addition, Boyer et al²⁴ showed that environmental contamination by *T. gondii* oocysts contributes substantially to acquisition of *T. gondii* and subsequent disease in people. These authors went on to suggest systematic screening of pregnant women and developing a vaccine that would have the potential to prevent the fetal disease caused by acquisition of *T. gondii* during gestation in North America.

Another important factor in the epidemiology of toxoplasmosis is the definitive host. Cats have an important role due to their close interaction with humans, and infected cats shed millions of oocysts in their feces that contaminate the environment.²⁵ The risk of infection via sporulated oocysts in human populations has been well documented.^{20,21} One study showed seropositivity for immunoglobulin (Ig)G and IgM antibodies to *T. gondii* in human populations living in Erechim, Rio Grande do Sul, Brazil, where there was a high risk (odds ratio >2.08) of infection in individuals who have had prior contact with soil.²¹ In addition, an environmental survey suggested that 22.58% (7/31) of soil samples obtained from gardens in public schools in the state of São Paulo, Brazil, were positive for *T. gondii*, and found that oocysts are widely distributed in areas belonging to public schools located in the region.²⁰ An outbreak of human toxoplasmosis was described in Santa Isabel do Ivaí, Paraná, Brazil, where about 426 people were infected, and water contaminated with *T. gondii* oocysts was considered to be the primary transmission route.²⁶ These data demonstrate the need to control oocyst shedding by cats; however, few studies have been conducted in this regard.

Like several other parasites, *T. gondii* can be controlled by education about sanitation, management of animals, including livestock and cats, treatment, and vaccination. Treatments are available to reduce clinical signs, but there are no drugs available that kill the parasite or cure the host of infection. There is just one commercial vaccine available (Toxovax®, MSD Animal Health, Summit, NJ, USA) that is used in the UK, New Zealand, France, and Ireland. This

vaccine comprises live tachyzoites of the incomplete S48 strain that has lost the ability to differentiate into tissue cysts in animals. The vaccine is licensed only for use in sheep and goats and should be administered prior to mating; however, there are some concerns about its safety because the vaccine can infect humans, and because it is a live vaccine, it has a short shelf-life.²⁷

The aim of this paper is to discuss recent advances in the epidemiology, biology, parasite diversity, and host–parasite interactions of *T. gondii*, and to review current vaccination strategies further to the recent papers by Garcia et al²⁵ and Innes et al⁶ and the prospect of future vaccines against this parasite.

Invasion of cells by *T. gondii*

Apicomplexan parasites, which include *T. gondii*, are obligate intracellular parasites.²⁸ Invasion of cells by *T. gondii* is a very complex event and key to the survival of the parasite inside hosts, since the organism cannot multiply outside cells.²⁹

The mechanisms via which tachyzoites invade host cells are regulated by many factors, including conoid movements, motility, and secretion of organelles (micronemes, rhoptries, and dense granules), and are calcium-dependent.^{30–32} This invasion is extremely rapid (15–40 seconds), depending on the sequential secretion of proteins by organelle complexes and is very important for survival of the parasite within the host cell.³³ After the tachyzoite finds the host cell, it starts to excrete proteins, first from micronemes and then from rhoptries, that enable attachment of the parasite to the cell, leading to formation of a moving junction, through which the parasite enters the cell.³⁴ Carruthers and Sibley³⁵ compared the kinetics of secretion from apical organelles, and observed that microneme proteins are initially secreted to form the host–parasite junction. Secretion from rhoptries is then involved in formation of the parasitophorous vacuole membrane, and secretion of dense granules starts only after the parasite is inside the parasitophorous vacuole. The parasitophorous vacuole membrane is considered to be a hybrid membrane, which means that secreted-excreted proteins from the parasite will be part of this membrane, and the parasitophorous vacuole does not fuse with host endosomes or lysosomes.³¹

Inside the parasitophorous vacuole, the tachyzoites multiply via a process called endodyogeny. This intracellular growth by the parasite leads to rupture of infected cells and subsequent infiltrates of neutrophils, eosinophils, and mononuclear cells at the site of infection. Progression of the infection, usually by day 6,³⁶ leads to development

of diffuse damage interrupted by multifocal necrosis. By about the third week after infection, tachyzoites start to disappear from visceral tissues and may localize as tissue cysts in neural and muscular tissues. Tachyzoites may persist longer in the spinal cord and brain than in visceral tissues because immunity is less effective in neural organs, and this persistence varies depending on the strain of *T. gondii* and the host species.³⁷ The host immune system is activated at a very early stage after infection, with involvement of natural killer cells, interferon gamma (IFN- γ), and interleukin (IL)-12 macrophages, and the innate immune system creating the right microenvironment for stimulation of the specific adaptive immune system.³⁸ As a consequence of the host immune response, the parasites are retained in tissue cysts and transform to bradyzoites, which multiply slowly within the cyst. In sheep and other livestock species, the tissue cysts can remain for the lifetime of the host, and this is also thought to be the case with humans.³⁹ *T. gondii* tissue cysts can be observed in the nervous system, eyes, organs, and muscles. When definitive hosts, ie, members of the cat family, become infected they shed unsporulated oocysts in their feces after a sexual phase in their intestinal cells. In the environment, unsporulated oocysts start sporogony and become sporulated (two sporocysts with four sporozoites each) and become infectious in 1–5 days depending on appropriate moist temperate environmental conditions.^{1,5}

Host cell invasion by sporozoites differs from infection by tachyzoites and bradyzoites. Following entry of sporozoites into cells, a large parasitophorous vacuole known as PV1 is formed initially. Sporozoites are not able to replicate inside PV1, because it lacks channels allowing absorption/uptake of nutrients. Therefore, a second vacuole, PV2, is formed in the cytoplasm, the parasite transfers across, and multiplication of the parasite takes place within VP2.⁴⁰

Potential proteins for vaccine use

About 1,360 specialized protein families have been described in *T. gondii*, which is a high number compared with related coccidian parasites.³⁴ Surface antigen glycoproteins (SAGs) are important for host cell attachment and host immune evasion, and *T. gondii* possesses 182 SAG-related sequences distributed across 14 chromosomes at 57 genomic loci.⁴¹ Additionally, the most abundant SAGs in the stages of *T. gondii* (SAG1 in tachyzoites, BSR4 in bradyzoites, and sporoSAG in sporozoites) are significantly divergent.^{35,42} Although SAG1 and BSR4 have different expression patterns, they are both members of the SAG1 family. Despite abundant expression of SporoSAG in infectious sporozoites,

serum from patients does not contain antibodies against SporoSAG, which is a member of the SAG2 subfamily and is significantly divergent from SAG1 and BSR4.^{35,39}

The main SAGs in *T. gondii* are SAG1 and SAG2, which are the most abundant proteins in tachyzoites.^{43,44} SAG1 is detected in the parasitophorous vacuole and in the intravacuolar membranous network; it is hydrophobic and has an acidic pH.⁴⁵ SAG1 has a role in penetration of the host cell by the tachyzoite during the initial stage of invasion, and along with SAG2 is involved in cell adhesion and invasion.^{38,46} Other stages of the parasite, ie, sporozoites and bradyzoites, lose all their surface proteins during stage differentiation to the tachyzoite and show specific proteins that mediate invasion of host cells.^{38,47} The antigenic differences in different stages of the parasite are not fully understood, but it is speculated that surface proteins from different stages interact with different tissues/cells in the host.⁴⁰ SAG1 and SAG2 have also been identified in the parasitophorous vacuole membrane and tubular vesicular network.⁴⁸ Several researchers have investigated SAG1 as a candidate vaccine.^{49–57}

As a member of the Apicomplexa phylum, *T. gondii* has an apical complex with specialized organelles used for host cell invasion, such as micronemes, rhoptries, and dense granules. Micronemes include adhesion proteins and a class of four aspartyl proteases (toxomepsin). Apical membrane antigen 1 (AMA1), a protein that is produced during intracellular multiplication of tachyzoites and initially localized in the microneme,⁵⁸ and together with RON proteins forms a ring-like structure known as the moving junction, leads to internalization of the parasite into a parasitophorous vacuole.⁵⁹ AMA1 plays a central role in host cell invasion, and antibodies against this protein block invasion of the parasite.⁶⁰ The importance of this protein during the process of host cell penetration was demonstrated when a *T. gondii* AMA1 knockout strain was unable to invade host cells.⁶¹ Because of this, AMA1 is considered to be a potential vaccine candidate.

About 20 dense granule proteins from *T. gondii* have been previously described.^{62–64} These proteins are secreted from the parasite into the parasitophorous vacuole where they participate in the remodeling and maintenance of this compartment. Dense granule proteins may be found in the intravacuolar membranous network and the parasitophorous vacuole membrane,⁶⁵ and are of fundamental importance to the survival of the parasite within the cell.⁴² GRA4 and GRA7 have been described also as candidate proteins for vaccine development.^{62,66,67}

The amino acid sequence deduced for GRA4 (40 kDa) indicates a proline-rich product with an internal hydrophobic

region and a potential site of N-glycosylation.⁶⁸ This protein was detected in serum from infected mice, providing evidence of the antigenicity of GRA4 protein synthesized from cells transfected with the plasmid DNA construct.⁶⁹

Alagunan et al⁷⁰ demonstrated that there is an interaction between ROP18, ROP8/2, and GRA7 leading to an increase in the virulence of *T. gondii* in mice. GRA7 has been shown in vitro to increase, by biochemical mechanisms, the turnover of immunity-related GTPases, thus potentially complementing the functions of other known virulence determinants, ROP18 and ROP5. This example reveals multiple layers of defense used by the parasite to counteract the innate immunity response in the host.⁷⁰

There are several rhoptry proteins described to date,⁷¹ and the most abundant is the ROP2-related family, which includes ROP2, ROP3, ROP4, ROP7, and ROP8. These share antigenic determinants, a very similar molecular weight (between 55 kDa and 60 kDa) and hydrophobic region(s).^{62,72} ROP2 is thought to serve as the molecular link between host cell mitochondria and the parasitophorous vacuole membrane. A study, which used ROP2-depleted parasites, observed that ROP2 was essential for multiplication and invasion of the parasite.⁷³ ROP2 was recognized by a human T cell clone and isolated from an immune donor, and is specific for the parasite protein and produces high levels of IFN- γ .⁷⁴ Additionally, ROP2 has been seen in all subgroups (types I, II, and III) and stages of the parasite.⁷⁵ For these reasons, ROP2 was identified as a candidate vaccine, and plasmids encoding the ROP2 antigen have been used to vaccinate mice.^{49,76}

Howe and Sibley⁷⁷ showed that 95% of *T. gondii* strains from Europe and North America (isolates from humans with and without acquired immune deficiency syndrome and from animals) belonged to three clonal lineages (genotypes I, II, and III), indicating low genetic diversity, which is explained by infrequent recombination during replication of diploid sexual stages in the definitive host. This may be applicable in Europe and North America, but in other parts of the world, such as South America, the *T. gondii* strains are highly diverse.⁷⁸ A recent study⁷⁹ examined more than 950 isolates representing worldwide diversity, and genotyped these using three independent sets of polymorphic DNA markers, sampling 30 loci distributed across all chromosomes as well as the plastid genome. The strains clustered into 138 unique genotypes, 15 haplogroups, and six major clades. This study also indicated that a small number of ancestral lineages gave rise to the existing diversity, the predominant highly clonal lineages in the northern hemisphere, and a selection of less

common genotypes showing greater evidence of recombination in parts of South America.

There are marked phenotypic variations between the genotypes; for example, while the RH strain (type I) is more virulent, ME49 (type II) and VEG (type III) are less virulent in mice.⁸⁰ Analysis of complex quantitative phenotypes such as virulence has revealed that chromosome VIIa controls differences in virulence between the highly virulent type I and avirulent type III strains. Also, members of the polymorphic protein kinases, such as ROP5, ROP16, and ROP18, contribute to phenotypic differences between the genotypes.^{81–83} However, the importance of these variations for development of vaccines remains unknown.

Immunity against *T. gondii*

T. gondii infection rarely produces clinical signs in the host, and severity of the disease is dependent on species, age of the host, sex hormones, pregnancy, immunological status, nutritional status of the host, strain (including differences between strains⁸⁴), parasite stage, and concomitant infection.⁸⁵ The mechanisms involved in host protection against infection are components of the innate and adaptive immune responses.

Animals (laboratory, domestic, livestock) and humans are clearly not identical, and many aspects of their anatomy, physiology, and genetics are different, including the development and function of their immune systems. Basically, the process by which an immune response is generated against the parasite is the same in all species, and involves induction and function of the innate and adaptive immune responses.

Toll-like receptors (TLRs) are a family of germ line-encoded receptors of the innate immune system, via which the host recognizes pathogen-associated molecular patterns.⁸⁶ In vertebrates, TLRs are essential for the recognition of parasites via the innate immune response and for induction of a clonally polarized, antigen-specific response by the adaptive immune system, mediated by B and T cells. TLRs are considered to be a conserved system, and there is no obvious interspecies variation between mammals. The nucleotide homology of human, livestock (cattle, small ruminants, pigs, horses), and domestic animal (cats, dogs) TLR genes ranges from 65% to 77%.⁸⁷

Since TLRs are associated with the adaptive immune response, study of adjuvants and specific antigens from *T. gondii* in livestock and domestic animals and their association with TLRs might help to develop vaccines for these species.⁸⁶ TLRs are essential for the development of the acquired immune response characterized by stimulation

of naïve CD4⁺ helper T cells toward the Th1 or Th2 phenotype. TLR-2 contributes to the resistance to high challenged doses of *T. gondii* in mice,⁸⁸ and TLR-11 and TLR-12 are very important in regulation of the immune response.^{89–92} Prominent expression of TLR-4 in the first trimester of pregnancy in humans has been reported, and lipopolysaccharide expressed in the cell wall of Gram-negative bacteria is recognized as the classic TLR-4 ligand, suggesting a possible protective role for maternally derived cells expressing these receptors.⁹³ TLR-11 plays a dominant role in recognition of *T. gondii* in mice; however, TLR-11 is represented in humans only by a pseudogene, so the major question of how innate and adaptive immune responses occur in the absence of TLR-11 remains unanswered.⁹² Despite the lack of this functional receptor in humans, studies in knockout mice (TLR-11^{−/−}) show that neutrophils are a crucial source for IFN- γ , which is required for protection against *T. gondii*.⁹⁴

Monocytes, neutrophils, and dendritic cells are recruited locally during the initial phases of infection and are important for resistance to *T. gondii*. This innate immune response produces the cytokine IL-12, which stimulates natural killer cells and T cells to produce the cytokine IFN- γ .⁹⁵ *T. gondii* antigens are processed by major histocompatibility complex class II antigen-presenting cells, and their peptides are presented to CD4⁺ cells to stimulate the adaptive immune response.

Studies using knockout mice deficient in B cells, CD4⁺, CD8⁺, and cytokines have demonstrated the importance of the adaptive immune response in resistance to toxoplasmosis.^{96,97} In mice, extremely elevated levels of IFN- γ and IL-18 result in lethal toxoplasmosis, whereas moderate levels of these cytokines cause nonlethal infection. Tumor necrosis factor (TNF)- α has an important role in resistance to toxoplasmosis, but high levels of this cytokine may contribute to pathogenesis. Elevated levels of IL-18, IFN- γ , IL-12, and TNF- α increase vascular permeability, and can lead to multiple organ failure and death of the animal.⁹⁸

CD4⁺ cells and CD8⁺ T lymphocytes are essential for the development of protective immunity and long-term survival during persistent infection, and this property is due to their ability to produce IFN- γ , a proinflammatory cytokine that is known to be a major mediator of resistance to *T. gondii*.⁹⁹ Depletion of this cytokine during the persistent phase of *T. gondii* infection in mice showed that continued production of IFN- γ is necessary for long-term survival.¹⁰⁰ Extracellular tachyzoites can be destroyed in the presence of specific antibodies and complement pathway.¹⁰¹ Anti-*T. gondii* antibodies may also prevent entry of the parasite into cells.

There are many questions regarding induction of innate and adaptive immune responses during *T. gondii* infection. Most studies that have evaluated immunity against this parasite were done in murine models. However, one important issue is the clear difference between animal species regarding their susceptibility to infection, and it is unclear how we could extrapolate results from one species to another.³⁹ Susceptibility to *T. gondii* infection may depend on differences in host–parasite interactions. This has been demonstrated in the development of toxoplasmic encephalitis in humans and mice. Human toxoplasmic encephalitis is associated with a loss of T cell function, whereas in mice it is associated with a defect in the CD8⁺ T cell response.¹⁰² Further, information on the immune response obtained from mice should not be extrapolated to pigs because of differences in their immune response mechanisms, such as the lack of an active nitric oxide pathway in pigs.^{103,104} Another important difference between animal species is found in IgM and IgG, eg, cats are not able to activate the classical complement pathway.¹⁰⁵ The major differences between the immune systems of animal species have been described in a recent review,¹⁰⁶ and included natural killer cells, distribution of Peyer's patches, immunoglobulin subclasses, and T cell receptor distribution.

Vaccines against *T. gondii*

Data obtained from Medline (PubMed, National Center for Biotechnology Information) using the key words “*Toxoplasma gondii*” and “vaccine”, focusing on the years 2009, 2010, 2011, 2012, through September 2013, yielded approximately 109 papers addressing vaccines against *T. gondii*, comprising 26 in 2009, 15 in 2010, 26 in 2011, 20 in 2012, and 22 in 2013. Most of these studies used mice (78%, 85/109) as an experimental model, six (5.5%) used sheep, and only two (1.8%) were in pigs. Interestingly, only one study attempted to reduce oocyst shedding in the feces of domestic cats,¹⁰⁷ given that these animals are considered to be the key in the transmission cycle of *T. gondii*.²⁷ Most of the mouse studies (Table 1) were conducted to test DNA vaccines (37.7%), with the main vector used being pVAX1 (a eukaryotic expression vector), and the main vaccine candidates inserted were the SAG1, ROP2, GRA4, and MIC3 genes. Some live virus vaccines expressing recombinant proteins were evaluated, and these studies showed promising levels of protection since anti-viral responses are similar to the immune responses required to control this parasite.^{50,108}

An important feature of *T. gondii* is that the main route of host infection is oral, with oocysts being the main form of infection in herbivores and tissue cysts being a route of

Table 1 *Toxoplasma gondii* vaccine studies in mouse models

Animal	Antigen and adjuvant	Route of immunization	Challenge	Aim	Results	Author(s)
C57BL/6, CD4 KO B cell and IL-10 KO NIH	TS-4 (temperature-sensitive mutant) 2×10^4 TS-4 strain	Intracameral	10^2 tachyzoites of RH strain ocularly	OT	Live TS-4 vaccine can be used for the prevention of OT	Lu et al ¹⁵³
CBA/J mice (H-2k)	TLA and TCP + <i>Lactobacillus casei</i> as adjuvant Exosomes secreted by DC pulsed with TLA	Intraperitoneal Subcutaneous	Orally 20 cysts of ME49 strain 25 cysts of 76K strain orally	BCB CT	Results suggest that <i>T. gondii</i> cytoskeleton proteins with <i>L. casei</i> are a good vaccine candidate This approach may be an effective alternative candidate vaccine against congenital toxoplasmosis	Martinez-Gomez et al ¹⁵⁴ Beauvillain et al ¹⁵⁵
BALB/c mice	pcDNA3.1-SAG1-MIC4 plasmid	Intranasally	Intraperitoneally 10^3 tachyzoites of RH strain	MR	Increase in survival rate and 14% higher survival rate than mice immunized with single-gene vaccines	Wang et al ¹⁵⁶
CBA/J	<i>Eimeria</i> antigen (rEA) + TLA	Intranasally	Orally 70 cysts of the 76K strain	BCB	Weak humoral and cellular immune response after intranasal immunization. However, mice had a 50% reduction in brain cysts	Hedhli et al ¹⁵²
CBA/J	Mic1-Mic3 KO and parental WT tachyzoites	Intraperitoneally/orally	ND	MR	The KO strain derived from type I strain behaved like type II strain	Moiré et al ¹⁵⁷
C3H/HeJ	Recombinant proteins ROP2 and ROP4	Subcutaneously	Intraperitoneally/five cysts of DX strain	BCB	Both antigens generated a strong systemic mixed Th1/Th2 response polarized toward IgG1 antibody isotype. In the immunized group brain cyst number was reduced by $\approx 46\%$	Dziadek et al ¹⁵⁸
C57BL/6, B6.MRL	Replication-deficient parasites that express the model antigen OVA	Intraperitoneally	Intraperitoneally/ 10^3 RH strain	MR	Immunization provided resistance to rechallenge; the RH parental strain was also protective	Jordan et al ¹⁵⁹
ICR mice	Multiantigenic DNA vaccine by attenuated <i>Salmonella typhimurium</i> (ZJ111/pSAG1-MIC3)	Orally	Intraperitoneally/ 500 tachyzoites of RH strain	MR	The vaccine produced partial protection against <i>T. gondii</i> challenge	Qu et al ¹⁶⁰
C57BL/6	Attenuated type I vaccine strain	Intraperitoneally	Intraperitoneally or orally/ ten or 100 cysts of ME49 strain	BCB	Immunization elicited CD8-immune T cells able to inhibit recrudescence of brain cysts	Gigley et al ¹⁶¹
BALB/c	DNA vaccine (pcDNA-SAG1) and pseudotype baculovirus expressing SAG1 (BV-G-SAG1)	Intramuscularly	Intraperitoneally/ 10^3 tachyzoites RH strain	MR	Compared with DNA vaccine (pcDNA/SAG1) BV-G-SAG1 induced higher levels of specific <i>T. gondii</i> antibodies and IFN- γ and survival rate of mice with BV-G-SAG1 was significantly improved	Fang et al ¹⁶⁴
Kunming	DNA vaccine (pVAX-MIC8)	Intramuscularly	Intraperitoneally/ 10^3 tachyzoites of RH strain	MR	Partial protection; MIC8 is a potential vaccine candidate against toxoplasmosis	Liu et al ¹⁶³
BALB/c Swiss-Webster	Recombinant virus + SAG2, influenza virus (FLU + SAG2)	Intranasally/subcutaneously	Orally/20 cysts of P-Br strain	BCB	Authors observed 85% of reduction in parasite burden	Machado et al ¹⁰⁸
C57BL/6 B6/J (IFN- γ)	Boosted with adenovirus (Ad + SAG2) KO strain/KU80 pyrimidine starvation	Intraperitoneally	Intraperitoneally/ 200 tachyzoites of RH strain	MR	A single immunization was able to produce a protective immunity to lethally challenge infection	Fox and Bzik ¹⁶²
C3H, C57BL/6	Extract of tobacco leaves expressing SAG1	Subcutaneously/orally	Orally/20 cysts of ME49 strain	BCB	Animals immunized by the parenteral route were better protected; use of plant has a potential for protecting humans and animals against toxoplasmosis	Laguía-Becher et al ¹⁶³

C57BL/6 C3H/HeJ	Recombinant proteins ROP2, ROP4, SAG1, and GRA4	Subcutaneously	Intraperitoneally/five cysts of DX strain	BCB	A significant reduction, ranging from 59% to 71%, in the formation of brain cysts in immunized animals	Dziadek et al ¹⁶⁴
BALB/c	DNA vaccine, SAG1, and ROP2	Intramuscularly	Intraperitoneally/ 10 ⁴ tachyzoites of RH strain	MR	Partial protection: vaccinated animals had longer survival time than controls	Hoseinian Khosroshahi et al ¹⁵⁵
Kunming	DNA vaccine, pVAX-ROP16	Intramuscularly	Intraperitoneally/ 10 ³ tachyzoites of RH strain	MR	pVAX-ROP16 dramatically increased the survival time (21.6–9.9 days) compared with control mice, which died 7 days after challenge	Yuan et al ¹⁶⁵
C57BL/6	DNA vaccine, pME18100/HSP70	Gene gun vaccination	Orally/ten cysts of Fukaya strain	BCB	All groups of deficient mice showed lower brain cysts than controls unvaccinated	Makino et al ¹⁶⁶
MyD88-deficient Swiss-Webster, C57BL/6 and KO mice	Adenovirus expressing SAG1 (AdSAG1), SAG2 (AdSAG2), or SAG3 (AdSAG3)	Subcutaneously	Orally/ten cysts of ME49 strain	MR	Vaccination with Adenovirus expressing SAG1 showed protective immunity in the highly susceptible C57BL/6 mice	Mendes et al ¹⁶⁷
C3H/HeN	Recombinant proteins, rROP2, rGRA4 plus CpG-ODN	Intramuscularly	Orally/20 cysts of ME49 strain	BCB	Immunized animals had reduced brain cysts by 62%–64%	Sánchez et al ¹⁶⁸
BALB/c mice	Recombinant pseudorabies virus, SAG1 or MIC3	Intramuscularly	Intraperitoneally/ 10 ³ tachyzoites of RH strain	MR	A partial protection of 66.7% was obtained in the mice immunized with a cocktail of SAG1-MIC3 rPRV	Nie et al ¹⁶⁹
CBA/J	DNA vaccine, RON4	Intramuscularly	Orally/70 cysts of 76K strain	BCB	RON4 showed no significant reduction in brain cyst load	Rashid et al ¹⁶⁹
Kunming	DNA vaccine, pVAX-ROP18	Intramuscularly	Intraperitoneally/ 10 ³ tachyzoites of RH strain	MR	immunization increased survival time (27.9 days) compared with control mice (7 days)	Yuan et al ¹⁷⁰
BALB/c	DNA vaccine, encoding GRA1 and SAG1	Intramuscularly	Intraperitoneally/ 10 ⁵ tachyzoites of RH strain	MR	Immunized animals showed a strong humoral and cellular immune response and had enhanced protection against challenge	Wu et al ¹⁷¹
Kunming	DNA vaccine, encoding ROP13/IL-18	Intramuscularly	Intraperitoneally/ 10 ³ tachyzoites of RH strain	MR	ROP13 and IL-18 increased the survival time (24.9 to 32.3 days) of mice	Wang et al ¹⁷¹
BALB/c	DNA vaccine, encoding Immune mapped protein I	Intramuscularly	Intraperitoneally/ 500 tachyzoites of RH strain	MR	Immunized mice showed an increased survival time (15.8 days)	Cui et al ¹⁷²
BALB/c	DNA vaccine, encoding <i>Toxoplasma</i> rhomboid protein I	Intramuscularly	Intraperitoneally/ 10 ³ tachyzoites of RH strain	MR	Immunized mice showed an increased survival time (12.5 days)	Li et al ¹⁷³
BALB/c	Recombinant proteins (rROP2, rROP4, rGRA4, rSAG1) incomplete Freund's adjuvant	Subcutaneously	Intraperitoneally/five cysts of DX strain	BCB	The animals immunized with rROP2 + rGRA4 + rSAG1, rROP2 + rROP4 + rGRA4 and rROP2 + rROP4 + rSAG1 showed reduction in the brain cyst number, 46%, 84%, and 77% respectively	Dziadek et al ¹⁴⁹
BALB/c	Recombinant protein SAG1 and SAG 2 encapsulated in PLG microparticles	Intraperitoneally	Subcutaneous/ 10 ⁴ tachyzoites of RH strain	MR	PLG-rSAG1/2-immunized animals showed a higher survival rate (83%)	Chuang et al ¹⁷⁴
Kunming	DNA vaccine, encoding MIC13	Intramuscularly	Intraperitoneally/10 ³ tachyzoites of RH strain and orally/ten cysts of PRU strain i	MR and BCB	Immunized mice showed an increased survival time (21.3 days) and reduction in the brain cyst number (900 cysts)	Yuan et al ¹⁷⁵
Kunming	Ultraviolet irradiation tachyzoites plus pidotimod adjuvant	Intraperitoneally	Intraperitoneally/ 10 ³ tachyzoites of RH strain	MR	Immunized mice showed an increased survival time (7 to over 30 days, in which 50% of the mice survived by day 30)	Zhao et al ¹⁷⁶

Abbreviations: BCB, brain cysts burden; DC, dendritic cells; OT, ocular toxoplasmosis; TLA, *Toxoplasma* lysate antigen; TCP, *Toxoplasma* cytoskeleton proteins; CT, congenital toxoplasmosis; KO, knockout; NIH, National Institutes of Health; IL, interleukin; MR, mortality rate; WT, wild-type; OVA, ovalbumin; ND, not done; IFN- γ , interferon-gamma; ICR, imprinting control region; CD, cluster of differentiation.

infection for pigs and humans, so local immunity in the gut via lymphocytes (mainly intraepithelial lymphocytes with CD8⁺ activity) and IgA is of fundamental importance in host resistance to the parasite.¹⁰⁹ However, after initial infection by sporozoites, the parasite transforms into tachyzoites, the rapidly dividing form of the parasite, and the sporozoSAG protein is nonimmunogenic during natural infection.¹¹⁰

Livestock

Sheep, goats, and pigs are more susceptible to disease following *T. gondii* infection than other livestock species and can harbor tissue cysts for life, whereas horses and cattle are less susceptible to infection and cysts containing bradyzoites are rarely detected in their tissues.^{1,39} However, animals raised for human consumption, including sheep, goats, chicken, cattle, horses, and pigs, are intermediate hosts and may serve as sources of *T. gondii* infection if their meat contains tissue cysts and is ingested raw or undercooked. This form of infection is described as carnivorism,^{85,111} and is thought to be a major transmission route for humans. Additionally, the disease burden of congenital toxoplasmosis, as represented by disability-adjusted life years, is the highest of all the food-borne pathogens.¹¹²

Toxovax is the only commercial vaccine available for congenital toxoplasmosis and is licensed for use only in sheep and goats. The manufacturer's recommendation is to use $\geq 10^5$ live tachyzoites of the S48 strain per animal. This dose should be given in a single injection of 2 mL via the intramuscular route at least 3 weeks prior to mating. Animals may be vaccinated from 5 months of age. The vaccine induces long-lasting immunity of at least 18 months without natural challenge. A rise in body temperature can be observed in animals following vaccination, and their meat should not be eaten for 42 days. The potential of Toxovax to prevent formation of *Toxoplasma* cysts in the ewe after a challenge is currently unknown.

Falcon and Freyre¹¹³ studied the capacity of a relatively low virulent strain to protect against formation of tissue cysts in sheep. Lambs were dosed orally with 10^6 sporulated oocysts of the ME-49 strain, and after 45 days, were challenged orally with 4×10^6 sporulated oocysts of the M3 strain. Unvaccinated control animals were infected with 4×10^6 sporulated oocysts of the M3 strain. Using a bioassay, the authors did not observe cysts in muscle or brain tissue from lambs that were previously infected with ME49; however, unvaccinated challenged control animals showed a high burden of *T. gondii* cysts in muscle and brain tissue.

Sheep have been used as a large animal model to determine the immune response to *T. gondii* induced by a DNA vaccine.^{66,114–117} The antigen genes tested were expressed in dense granules and rhoptries, ie, GRA1, GRA4, GRA6, GRA7, and ROP1. These were used as DNA vaccines in different types of adjuvant formulations, such as liposomes. Ovine CD154 was added at the time of vaccination to enhance stimulation of the immune response. CD154 is expressed as a type II integral membrane protein on the surface of activated T cells, basophils, and mast cells. The results showed that intramuscular injection of sheep with DNA liposomes formulated to contain plasmids coding for GRA proteins is an effective system that induces a significant mixed Th1/Th2 response, while intramuscular injection of ROP1 induced a Th1-specific immune response against *T. gondii*. Li et al⁵¹ investigated the immune response in sheep after injection of plasmids encoding *T. gondii* SAG1 and ROP1. Injection of ROP1 produced a better immune response than SAG1. However, these studies did not indicate sufficient protection against *T. gondii* challenge.

Mevelec et al¹¹⁸ showed the effectiveness of a mic1 and mic3 gene knockout (Mic1–3 KO) RH strain against *Toxoplasma* abortion in sheep. Sheep were inoculated subcutaneously with 10^5 Mic1–3 KO tachyzoites, and showed a mild febrile and parasite-specific IgG antibody response. Ewes were mated 2 months after vaccination and were challenged orally at mid gestation with different doses of oocysts from the PRU strain (100–400 sporulated oocysts). After challenge, the animals showed a slight febrile response, whereas unvaccinated ewes developed a more severe febrile response. All unvaccinated ewes aborted, while 62%–91% of lambs born to the vaccinated sheep were viable, and did not show clinical signs of infection. The authors tested the Toxovax (S48 strain) vaccine as well, and showed that the mutant strain was as effective as the S48 strain. The mutant strain, at a dose of 10^5 tachyzoites, induced a level of protection comparable with that of 2×10^6 S48 tachyzoites.

There are only three studies that have attempted to vaccinate goats against toxoplasmosis.^{119–121} Two of these studies^{119,120} used goats with related parasites (*Hammondia hammondi*) and *H. heydorni* to protect against congenital toxoplasmosis in does, and reported partial protection using *H. hammondi* but no promising effect using *H. heydorni*. The last study¹²¹ show good efficacy of the S48 strain in protecting does against congenital infection in France, one of the countries in which Toxovax is licensed. It is still necessary to conduct more studies using this host in vaccine experiments, given that goats are one of the species most

susceptible to *T. gondii* infection.¹²² Moreover, consumption of *T. gondii*-infected raw or undercooked goat meat and unpasteurized goat milk containing tachyzoites constitutes a significant infection risk in humans.^{123–125}

Clinical signs of toxoplasmosis in pigs are considered rare, and abortion in sows is not common but can occur.^{126,127} Tissue cysts in pork can persist for more than 2 years, and these are one of the most important sources of *T. gondii* infection in humans.^{23,128} Because of the potential public health risk from undercooked infected pork, a vaccine for pigs needs to be able to reduce or prevent formation of tissue cysts.

Verhelst et al¹²⁹ showed that GRA7 and MIC3 were able to induce a good humoral immune response in pigs experimentally challenged with *T. gondii* tissue cysts. Cunha et al¹³⁰ evaluated protection against formation of tissue cysts in pigs immunized intranasally with a crude rhoptry protein preparation of *T. gondii* plus Quil-A®. The vaccinated and challenged group showed 41.6% protection against tissue cyst formation versus 6.5% protection in the adjuvant control group.

Excreted-secreted antigens (proteins discharged from organelles of the parasite during invasion of host cells) from *T. gondii* mixed with Freund's adjuvant were used as a vaccine in pigs to evaluate the humoral and cellular immune response and protection against an intraperitoneal challenge with 10⁷ tachyzoites of the GJS strain.¹³¹ The authors showed a cellular immune response associated with production of IFN- γ and IL-4, and a humoral response mainly against antigens with molecular masses of 34–116 kDa. Following challenge, the immunized pigs remained clinically normal except for a rise in temperature, while the control pigs developed higher fever and clinical signs of toxoplasmosis. A reduction in formation of tissue cysts in muscles was found in the vaccinated animals.

Cats

Felines are the only definitive hosts able to shed oocysts via their feces, and domestic cats play an important role in the transmission of *T. gondii*. Cats are widespread globally and are considered to be among the worst non-native invasive species in the world. Moreover, they live in close proximity to humans.¹³² Infected cats can shed millions of oocysts in their feces,²⁵ that may contaminate soil, water, and food. The significance of the environmental spread of oocysts produced by wild cats is unknown.

The first studies to immunize cats to prevent oocyst shedding were reported by Frenkel et al¹³³ and Freyre et al.¹³⁴ These authors, along with Mateus-Pinilla et al,¹³⁵ used a

T-263 strain that had been transformed in the laboratory and lost the ability to complete the sexual cycle in enteroepithelial cells in cats as a vaccine. The main concern about use of the T-263 strain as a vaccine is its short shelf-life and need for production in mice. 60Co-irradiation tachyzoites were tested in cats in order to prevent/reduce oocyst shedding; however, the authors did not observe a significant reduction in oocysts in the vaccinated cats.^{136,137} Garcia et al,²⁵ and more recently Zulpo et al,¹⁰⁷ tested a vaccine based on rhoptry proteins administered by the intranasal and rectal routes in cats and found that the immunized animals eliminated 90.8% and 98% fewer oocysts than the control group, respectively.

Mice

Mice are the experimental model of choice for *Toxoplasma* vaccine studies, as shown in Table 1. They are easier to manipulate and inexpensive to maintain compared with domestic and livestock animals, and their immunology is very well characterized. Many studies have used mice to investigate vaccines (Table 1). However, comparison of their results is difficult because of the different types of immunization, challenge routes (with different forms of parasite), and mouse strains used. Several types of approach have been used, ie, attenuated live vaccines, knockout strains, DNA vaccines, attenuated recombinant viruses, and recombinant proteins, and all described partial protection, mainly against mortality due to acute infection and tissue cyst burden.

Biological models for vaccine studies

Mice and rats are the main biological models used to study toxoplasmosis in vivo. While mice are sensitive, rats, like humans, are relatively resistant to *T. gondii*. Murine susceptibility to *T. gondii* is under multigenic control, with at least one of the genes linked to the major histocompatibility complex (H2 locus).¹³⁸ In addition, reduction of cyst numbers in the brain and encephalitis is mediated by the *L^d* gene in the D region of the H2 complex in mice.¹³⁹

Sequencing the mouse genome has shown that approximately 99% of mouse genes have a homolog in the human genome.¹⁴⁰ However, there are differences between the immune systems of mice and humans^{141,142} and between mice and domestic animals.^{86,106} These differences need to be considered before data obtained from mice can be extrapolated to humans or domestic animals.

Mice are useful for in vivo vaccine studies against *T. gondii*, and with the availability of knockout gene mouse

strains, they will continue to be the first choice for vaccine trials. Other animal models of human toxoplasmosis have been used, including the rabbit,¹⁴³ hamster,^{144,145} sheep,^{146,147} and pig.^{130,148,149} However, extrapolation of the results observed in experiments with animals is a difficult task, and a good biological model for ocular, congenital, recrudescence, and acute and persistent *T. gondii* infection would be very helpful in the prevention of human toxoplasmosis.

Prospects for future vaccines

Vaccination against bacterial and viral diseases is widespread, routine, and successful, but only a few vaccines for veterinary protozoan diseases have been developed successfully, and thus far none are available for human use. Future studies aiming to develop *T. gondii* vaccines should focus on parasite antigens able to trigger a protective immune response and investigate immunization routes and vaccine delivery strategies. To be effective, a protective vaccine needs to stimulate both humoral and cellular immune responses, which is difficult to achieve with killed vaccines. Concerns regarding live vaccines are mainly to do with their safety and short shelf-life. It would also be desirable to create a vaccine that would enable differentiation between vaccinated and infected animals. Thus, the use of viruses as vectors and knockout strains could be a good strategy to develop vaccines against this parasite.

Based on disability-adjusted life-year papers, *T. gondii* is considered one of the most significant food-borne pathogens,^{112,150} and there is no treatment that is able to eliminate the parasite from human tissue; this is important when considering the brain (psychiatric disorders and toxoplasmic encephalitis) and eye (ocular disease), and what enforces the development of a vaccine against this parasite.

Use of relevant animal species is important in the study of protective immune responses to *T. gondii*, because they address questions relating to specific host–parasite interactions. More studies should be done using cats in order to answer important questions, such as: Which approach should be used to achieve an intestinal immune response against *T. gondii* to diminish oocyst shedding, ie, live or killed vaccines? What is the best route of immunization, ie, systemic or oral? Which proteins should be used in recombinant vaccines? What is the potential of cats to shed oocysts after reinfection? Do different genotypes induce/require a different immune response?

Goats are one of the most susceptible domestic animal species with respect to toxoplasmosis, and the main clinical signs in adult goats are reproductive disorders, although some animals

may develop anorexia, prostration, fever, and mastitis.^{151,152} Unfortunately, very few studies that have attempted to produce a vaccine against *T. gondii* for goats. Further, despite Toxovax being licensed for use in dogs, it is only available in a limited number of countries, so there is a need for more studies looking at developing vaccines in goats.

Information obtained so far indicates that future vaccines for *T. gondii* should be developed against several different targets, ie, to prevent oocyst shedding by cats, prevent formation of tissue cysts in animals raised for human consumption, and prevent abortion or fetal malformation in sheep, goats, and women.

A vaccine against ocular toxoplasmosis as a consequence of acquired infection in regions with a high level of ocular toxoplasmosis, such as southern Brazil, should also be addressed. Development of a type of immunomodulator to be used in patients with chronic ocular toxoplasmosis could be a good approach to avoid future reactivation.

Acknowledgments

The authors would like to thank the Coordenação de Aperfeiçoamento de Pessoal de Nivel Superior (CAPES 10259-12-0) and Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq, 474924/2011-4; 303901/2012-8), the Scottish Government (Rural and Environment Science and Analytical Services), and the Moredun Foundation and Creative Science Company for financial support.

Disclosure

The authors report no conflicts of interest in this work.

References

1. Dubey JP, Thulliez P. Persistence of tissue cysts in edible tissues of cattle fed *Toxoplasma gondii* oocysts. *Am J Vet Res*. 1993;54(2):270–273.
2. Prestrud KW, Dubey JP, Asbakk K, Fuglei E, Su C. First isolate of *Toxoplasma gondii* from arctic fox (*Vulpes lagopus*) from Svalbard. *Vet Parasitol*. 2008;151(2–4):110–114.
3. Canon-Franco WA, Araujo FA, Lopez-Orozco N, et al. *Toxoplasma gondii* in free-ranging wild small felids from Brazil: molecular detection and genotypic characterization. *Vet Parasitol*. 2013;197(3–4):462–469.
4. Nieto SO, Melendez RD. Seroprevalence of *Toxoplasma gondii* in goats from arid zones of Venezuela. *J Parasitol*. 1998;84(1):190–191.
5. Dubey JP, Fair PA, Sundar N, et al. Isolation of *Toxoplasma gondii* from bottlenose dolphins (*Tursiops truncatus*). *J Parasitol*. 2008;94(4):821–823.
6. Innes EA, Bartley PM, Maley S, Katzer F, Buxton D. Veterinary vaccines against *Toxoplasma gondii*. *Mem Inst Oswaldo Cruz*. 2009;104(2):246–251.
7. Carellos EV, Caiaffa WT, Andrade GM, Abreu MN, Januario JN. Congenital toxoplasmosis in the state of Minas Gerais, Brazil: a neglected infectious disease? *Epidemiol Infect*. 2013;1–12.
8. Jones JL, Lopez A, Wilson M, Schulkin J, Gibbs R. Congenital toxoplasmosis: a review. *Obstet Gynecol Surv*. 2001;56(5):296–305.
9. Tenter AM, Heckeroth AR, Weiss LM. *Toxoplasma gondii*: from animals to humans. *Int J Parasitol*. 2000;30(12–13):1217–1258.

10. Freyre A, Falcon J, Mendez J, Rodriguez A, Correa L, Gonzalez M. *Toxoplasma gondii*: partial cross-protection among several strains of the parasite against congenital transmission in a rat model. *Exp Parasitol*. 2006;112(1):8–12.
11. Dubey JP. Strategies to reduce transmission of *Toxoplasma gondii* to animals and humans. *Vet Parasitol*. 1996;64(1–2):65–70.
12. Carneiro AC, Andrade GM, Costa JG, et al. Genetic characterization of *Toxoplasma gondii* revealed highly diverse genotypes for isolates from newborns with congenital toxoplasmosis in southeastern Brazil. *J Clin Microbiol*. 2013;51(3):901–907.
13. Leport C, Franck J, Chene G, et al. Immunoblot profile as predictor of toxoplasmic encephalitis in patients infected with human immunodeficiency virus. *Clin Diagn Lab Immunol*. 2001;8(3):579–584.
14. Luft BJ, Hafner R, Korzun AH, et al. Toxoplasmic encephalitis in patients with the acquired immunodeficiency syndrome. Members of the ACTG 077p/ANRS 009 Study Team. *N Engl J Med*. 1993;329(14):995–1000.
15. Silveira C, Belfort R Jr, Muccioli C, et al. A follow-up study of *Toxoplasma gondii* infection in southern Brazil. *Am J Ophthalmol*. 2001;131(3):351–354.
16. Carter CJ. Toxoplasmosis and polygenic disease susceptibility genes: extensive *Toxoplasma gondii* host/pathogen interactome enrichment in nine psychiatric or neurological disorders. *J Pathog*. 2013;2013:965046.
17. Flegr J. Influence of latent *Toxoplasma* infection on human personality, physiology and morphology: pros and cons of the *Toxoplasma*-human model in studying the manipulation hypothesis. *J Exp Biol*. 2013; 216 Pt 1:127–133.
18. Navarro IT, Vidotto O, Giraldo N, Mitsuka R. [Resistance of *Toxoplasma gondii* to sodium chloride and condiments in pork sausage]. *Bol Oficina Sanit Panam*. 1992;112(2):138–143. Portuguese.
19. Dias RA, Navarro IT, Ruffolo BB, Bugni FM, Castro MV, Freire RL. *Toxoplasma gondii* in fresh pork sausage and seroprevalence in butchers from factories in Londrina, Parana State, Brazil. *Rev Inst Med Trop Sao Paulo*. 2005;47(4):185–189.
20. dos Santos TR, Nunes CM, Luvizotto MC, et al. Detection of *Toxoplasma gondii* oocysts in environmental samples from public schools. *Vet Parasitol*. 2010;171(1–2):53–57.
21. Jones JL, Muccioli C, Belfort R Jr, Holland GN, Roberts JM, Silveira C. Recently acquired *Toxoplasma gondii* infection, Brazil. *Emerg Infect Dis*. 2006;12(4):582–587.
22. Hill D, Coss C, Dubey JP, et al. Identification of a sporozoite-specific antigen from *Toxoplasma gondii*. *J Parasitol*. 2011;97(2):328–337.
23. Dubey JP, Hill DE, Jones JL, et al. Prevalence of viable *Toxoplasma gondii* in beef, chicken, and pork from retail meat stores in the United States: risk assessment to consumers. *J Parasitol*. 2005;91(5):1082–1093.
24. Boyer K, Hill D, Mui E, et al. Unrecognized ingestion of *Toxoplasma gondii* oocysts leads to congenital toxoplasmosis and causes epidemics in North America. *Clin Infect Dis*. 2011;53(11):1081–1089.
25. Garcia JL, Navarro IT, Biazzone L, et al. Protective activity against oocyst shedding in cats vaccinated with crude rhoptry proteins of the *Toxoplasma gondii* by the intranasal route. *Vet Parasitol*. 2007;145(3–4):197–206.
26. de Moura L, Bahia-Oliveira LM, Wada MY, et al. Waterborne toxoplasmosis, Brazil, from field to gene. *Emerg Infect Dis*. 2006;12(2):326–329.
27. Garcia JL. Vaccination concepts against *Toxoplasma gondii*. *Expert Rev Vaccines*. 2009;8(2):215–225.
28. Etzion Z, Murray MC, Perkins ME. Isolation and characterization of rhoptries of *Plasmodium falciparum*. *Mol Biochem Parasitol*. 1991;47(1):51–61.
29. Saffer LD, Schwartzman JD. A soluble phospholipase of *Toxoplasma gondii* associated with host cell penetration. *J Protozool*. 1991;38(5):454–460.
30. Nichols BA, Chiappino ML. Cytoskeleton of *Toxoplasma gondii*. *J Protozool*. 1987;34(2):217–226.
31. Bonhomme A, Bouchot A, Pezzella N, Gomez J, Le Moal H, Pinon JM. Signaling during the invasion of host cells by *Toxoplasma gondii*. *FEMS Microbiol Rev*. 1999;23(5):551–561.
32. Bouchot A, Zierold K, Bonhomme A, et al. Tachyzoite calcium changes during cell invasion by *Toxoplasma gondii*. *Parasitol Res*. 1999;85(10):809–818.
33. Hoff EF, Carruthers VB. Is *Toxoplasma* egress the first step in invasion? *Trends Parasitol*. 2002;18(6):251–255.
34. Wasmuth J, Daub J, Peregrin-Alvarez JM, Finney CA, Parkinson J. The origins of apicomplexan sequence innovation. *Genome Res*. 2009;19(7):1202–1213.
35. Carruthers VB, Sibley LD. Sequential protein secretion from three distinct organelles of *Toxoplasma gondii* accompanies invasion of human fibroblasts. *Eur J Cell Biol*. 1997;73(2):114–123.
36. Parker GA, Langloss JM, Dubey JP, Hoover EA. Pathogenesis of acute toxoplasmosis in specific-pathogen-free cats. *Vet Pathol*. 1981;18(6):786–803.
37. Dubey JP, Lago EG, Gennari SM, Su C, Jones JL. Toxoplasmosis in humans and animals in Brazil: high prevalence, high burden of disease, and epidemiology. *Parasitology*. 2012;139(11):1375–1424.
38. Dupont CD, Christian DA, Hunter CA. Immune response and immunopathology during toxoplasmosis. *Semin Immunopathol*. 2012;34(6):793–813.
39. Innes EA. Toxoplasmosis: comparative species susceptibility and host immune response. *Comp Immunol Microbiol Infect Dis*. 1997;20(2):131–138.
40. Tilley M, Fichera ME, Jerome ME, Roos DS, White MW. *Toxoplasma gondii* sporozoites form a transient parasitophorous vacuole that is impermeable and contains only a subset of dense-granule proteins. *Infect Immun*. 1997;65(11):4598–4605.
41. Wasmuth JD, Pszeny V, Haile S, et al. Integrated bioinformatic and targeted deletion analyses of the SRS gene superfamily identify SRS29C as a negative regulator of *Toxoplasma* virulence. *MBio*. 2012;3(6).
42. Crawford J, Grujic O, Bruic E, Czjzek M, Grigg ME, Boulanger MJ. Structural characterization of the bradyzoite surface antigen (BSR4) from *Toxoplasma gondii*, a unique addition to the surface antigen glycoprotein 1-related superfamily. *J Biol Chem*. 2009;284(14):9192–9198.
43. Couvreur G, Sadak A, Fortier B, Dubremetz JF. Surface antigens of *Toxoplasma gondii*. *Parasitology*. 1988;97 Pt 1:1–10.
44. Grimwood J, Smith JE. *Toxoplasma gondii*: the role of parasite surface and secreted proteins in host cell invasion. *Int J Parasitol*. 1996;26(2):169–173.
45. McLeod R, Mack D, Brown C. *Toxoplasma gondii* – new advances in cellular and molecular biology. *Exp Parasitol*. 1991;72(1):109–121.
46. Grimwood J, Mineo JR, Kasper LH. Attachment of *Toxoplasma gondii* to host cells is host cell cycle dependent. *Infect Immun*. 1996;64(10):4099–4104.
47. Gross U, Bohne W, Soete M, Dubremetz JF. Developmental differentiation between tachyzoites and bradyzoites of *Toxoplasma gondii*. *Parasitol Today*. 1996;12(1):30–33.
48. Achbarou A, Mercereau-Puijalon O, Sadak A, et al. Differential targeting of dense granule proteins in the parasitophorous vacuole of *Toxoplasma gondii*. *Parasitology*. 1991;103 Pt 3:321–329.
49. Dziadek B, Gatkowska J, Grzybowski M, Dziadek J, Dzitko K, Długowska H. *Toxoplasma gondii*: the vaccine potential of three trivalent antigen-cocktails composed of recombinant ROP2, ROP4, GRA4 and SAG1 proteins against chronic toxoplasmosis in BALB/c mice. *Exp Parasitol*. 2012;131(1):133–138.
50. Shang L, Liu Q, Liu W, et al. Protection in mice immunized with a heterologous prime-boost regime using DNA and recombinant pseudorabies expressing TgSAG1 against *Toxoplasma gondii* challenge. *Vaccine*. 2009;27(21):2741–2745.
51. Li B, Oledzka G, McFarlane RG, et al. Immunological response of sheep to injections of plasmids encoding *Toxoplasma gondii* SAG1 and ROP1 genes. *Parasite Immunol*. 2010;32(9–10):671–683.

52. Hedhli D, Dimier-Poisson I, Judge JW, Rosenberg B, Mevelec MN. Protective immunity against *Toxoplasma* challenge in mice by coadministration of *T. gondii* antigens and *Eimeria* profilin-like protein as an adjuvant. *Vaccine*. 2009;27(16):2274–2281.
53. Liu Q, Shang L, Jin H, Wei F, Zhu XQ, Gao H. The protective effect of a *Toxoplasma gondii* SAG1 plasmid DNA vaccine in mice is enhanced with IL-18. *Res Vet Sci*. 2010;89(1):93–97.
54. Fang R, Feng H, Nie H, et al. Construction and immunogenicity of pseudotype baculovirus expressing *Toxoplasma gondii* SAG1 protein in BALB/c mice model. *Vaccine*. 2010;28(7):1803–1807.
55. Hoseinian Khosroshahi K, Ghaffarifar F, D'Souza S, Sharifi Z, Dalimi A. Evaluation of the immune response induced by DNA vaccine cocktail expressing complete SAG1 and ROP2 genes against toxoplasmosis. *Vaccine*. 2011;29(4):778–783.
56. Nie H, Fang R, Xiong BQ, et al. Immunogenicity and protective efficacy of two recombinant pseudorabies viruses expressing *Toxoplasma gondii* SAG1 and MIC3 proteins. *Vet Parasitol*. 2011;181(2–4):215–221.
57. Wu XN, Lin J, Lin X, Chen J, Chen ZL, Lin JY. Multicomponent DNA vaccine-encoding *Toxoplasma gondii* GRA1 and SAG1 primes: anti-*Toxoplasma* immune response in mice. *Parasitol Res*. 2012;111(5):2001–2009.
58. Hehl AB, Lekutis C, Grigg ME, et al. *Toxoplasma gondii* homologue of plasmodium apical membrane antigen 1 is involved in invasion of host cells. *Infect Immun*. 2000;68(12):7078–7086.
59. Tonkin ML, Roques M, Lamarque MH, et al. Host cell invasion by apicomplexan parasites: insights from the co-structure of AMA1 with a RON2 peptide. *Science*. 2011;333(6041):463–467.
60. Hodder AN, Crewther PE, Anders RF. Specificity of the protective antibody response to apical membrane antigen 1. *Infect Immun*. 2001;69(5):3286–3294.
61. Mital J, Meissner M, Soldati D, Ward GE. Conditional expression of *Toxoplasma gondii* apical membrane antigen-1 (TgAMA1) demonstrates that TgAMA1 plays a critical role in host cell invasion. *Mol Biol Cell*. 2005;16(9):4341–4349.
62. Leriche MA, Dubremetz JF. Characterization of the protein contents of rhoptries and dense granules of *Toxoplasma gondii* tachyzoites by subcellular fractionation and monoclonal antibodies. *Mol Biochem Parasitol*. 1991;45(2):249–259.
63. Metsis A, Pettersen E, Petersen E. *Toxoplasma gondii*: characterization of a monoclonal antibody recognizing antigens of 36 and 38 kDa with acid phosphatase activity located in dense granules and rhoptries. *Exp Parasitol*. 1995;81(4):472–479.
64. Okada T, Marmansari D, Li ZM, et al. A novel dense granule protein, GRA22, is involved in regulating parasite egress in *Toxoplasma gondii*. *Mol Biochem Parasitol*. 2013;189(1–2):5–13.
65. Masatani T, Matsuo T, Tanaka T, et al. TgGRA23, a novel *Toxoplasma gondii* dense granule protein associated with the parasitophorous vacuole membrane and intravacuolar network. *Parasitol Int*. 2013;62(4):372–379.
66. Hisczyska-Sawicka E, Oledzka G, Holec-Gasior L, et al. Evaluation of immune responses in sheep induced by DNA immunization with genes encoding GRA1, GRA4, GRA6 and GRA7 antigens of *Toxoplasma gondii*. *Vet Parasitol*. 2011;177(3–4):281–289.
67. Jongert E, Melkebeek V, De Craeye S, Dewit J, Verhelst D, Cox E. An enhanced GRA1-GRA7 cocktail DNA vaccine primes anti-*Toxoplasma* immune responses in pigs. *Vaccine*. 2008;26(8):1025–1031.
68. Mevelec MN, Chardes T, Mercereau-Puijalon O, et al. Molecular cloning of GRA4, a *Toxoplasma gondii* dense granule protein, recognized by mucosal IgA antibodies. *Mol Biochem Parasitol*. 1992;56(2):227–238.
69. Desolme B, Mevelec MN, Buzoni-Gatel D, Bout D. Induction of protective immunity against toxoplasmosis in mice by DNA immunization with a plasmid encoding *Toxoplasma gondii* GRA4 gene. *Vaccine*. 2000;18(23):2512–2521.
70. Alagunan A, Fentress SJ, Tang K, Wang Q, Sibley LD. *Toxoplasma* GRA7 effector increases turnover of immunity-related GTPases and contributes to acute virulence in the mouse. *Proc Natl Acad Sci U S A*. 2014;111(3):1126–1131.
71. Camejo A, Gold DA, Lu D, et al. Identification of three novel *Toxoplasma gondii* rhoptry proteins. *Int J Parasitol*. 2014;44(2):147–160.
72. Beckers CJ, Dubremetz JF, Mercereau-Puijalon O, Joiner KA. The *Toxoplasma gondii* rhoptry protein ROP 2 is inserted into the parasitophorous vacuole membrane, surrounding the intracellular parasite, and is exposed to the host cell cytoplasm. *J Cell Biol*. 1994;127(4):947–961.
73. Nakaar V, Ngo HM, Aaronson EP, Coppens I, Stedman TT, Joiner KA. Pleiotropic effect due to targeted depletion of secretory rhoptry protein ROP2 in *Toxoplasma gondii*. *J Cell Sci*. 2003;116 Pt 11:2311–2320.
74. Saavedra R, de Meuter F, Decourt JL, Herion P. Human T cell clone identifies a potentially protective 54-kDa protein antigen of *Toxoplasma gondii* cloned and expressed in *Escherichia coli*. *J Immunol*. 1991;147(6):1975–1982.
75. El Hajj H, Demey E, Poncet J, et al. The ROP2 family of *Toxoplasma gondii* rhoptry proteins: proteomic and genomic characterization and molecular modeling. *Proteomics*. 2006;6(21):5773–5784.
76. Vercammen M, Scorza T, Huygen K, et al. DNA vaccination with genes encoding *Toxoplasma gondii* antigens GRA1, GRA7, and ROP2 induces partially protective immunity against lethal challenge in mice. *Infect Immun*. 2000;68(1):38–45.
77. Howe DK, Sibley LD. *Toxoplasma gondii* comprises three clonal lineages: correlation of parasite genotype with human disease. *J Infect Dis*. 1995;172(6):1561–1566.
78. Dubey JP, Sundar N, Gennari SM, et al. Biologic and genetic comparison of *Toxoplasma gondii* isolates in free-range chickens from the northern Para state and the southern state Rio Grande do Sul, Brazil revealed highly diverse and distinct parasite populations. *Vet Parasitol*. 2007;143(2):182–188.
79. Su C, Khan A, Zhou P, et al. Globally diverse *Toxoplasma gondii* isolates comprise six major clades originating from a small number of distinct ancestral lineages. *Proc Natl Acad Sci U S A*. 2012;109(15):5844–5849.
80. Sibley LD, Boothroyd JC. Virulent strains of *Toxoplasma gondii* comprise a single clonal lineage. *Nature*. 1992;359(6390):82–85.
81. Behnke MS, Khan A, Wootton JC, Dubey JP, Tang K, Sibley LD. Virulence differences in *Toxoplasma* mediated by amplification of a family of polymorphic pseudokinases. *Proc Natl Acad Sci U S A*. 2011;108(23):9631–9636.
82. Su C, Howe DK, Dubey JP, Ajioka JW, Sibley LD. Identification of quantitative trait loci controlling acute virulence in *Toxoplasma gondii*. *Proc Natl Acad Sci U S A*. 2002;99(16):10753–10758.
83. Taylor S, Barragan A, Su C, et al. A secreted serine-threonine kinase determines virulence in the eukaryotic pathogen *Toxoplasma gondii*. *Science*. 2006;314(5806):1776–1780.
84. Howe DK, Sibley LD. *Toxoplasma gondii*: analysis of different laboratory stocks of the RH strain reveals genetic heterogeneity. *Exp Parasitol*. 1994;78(2):242–245.
85. Dubey JP. Toxoplasmosis. *J Am Vet Med Assoc*. 1994;205(11):1593–1598.
86. Jungi TW, Farhat K, Burgener IA, Werling D. Toll-like receptors in domestic animals. *Cell Tissue Res*. 2011;343(1):107–120.
87. Turin L, Riva F. Toll-like receptor family in domestic animal species. *Crit Rev Immunol*. 2008;28(6):513–538.
88. Mun HS, Aosai F, Chen M, et al. Pathogenicity of *Toxoplasma gondii* through B-2 cell-mediated downregulation of host defense responses. *Microbiol Immunol*. 2003;47(7):533–542.
89. Raetz M, Kibardin A, Sturge CR, et al. Cooperation of TLR12 and TLR11 in the IRF8-dependent IL-12 response to *Toxoplasma gondii* profilin. *J Immunol*. 2013;191(9):4818–4827.
90. Andrade WA, Souza Mdo C, Ramos-Martinez E, et al. Combined action of nucleic acid-sensing Toll-like receptors and TLR11/TLR12 heterodimers imparts resistance to *Toxoplasma gondii* in mice. *Cell Host Microbe*. 2013;13(1):42–53.
91. Wujcicka W, Wilczynski J, Nowakowska D. Do the placental barrier, parasite genotype and Toll-like receptor polymorphisms contribute to the course of primary infection with various *Toxoplasma gondii* genotypes in pregnant women? *Eur J Clin Microbiol Infect Dis*. November 30, 2013. [Epub ahead of print.]

92. Pifer R, Yarovsky F. Innate responses to *Toxoplasma gondii* in mice and humans. *Trends Parasitol.* 2011;27(9):388–393.
93. Schatz F, Kayisli UA, Vatanaslar E, et al. Toll-like receptor 4 expression in decidual cells and interstitial trophoblasts across human pregnancy. *Am J Reprod Immunol.* 2012;68(2):146–153.
94. Sturge CR, Benson A, Raetz M, et al. TLR-independent neutrophil-derived IFN-gamma is important for host resistance to intracellular pathogens. *Proc Natl Acad Sci U S A.* 2013;110(26):10711–10716.
95. Miller CM, Boulter NR, Ikin RJ, Smith NC. The immunobiology of the innate response to *Toxoplasma gondii*. *Int J Parasitol.* 2009;39(1):23–39.
96. Kang H, Remington JS, Suzuki Y. Decreased resistance of B cell-deficient mice to infection with *Toxoplasma gondii* despite unimpaired expression of IFN-gamma, TNF-alpha, and inducible nitric oxide synthase. *J Immunol.* 2000;164(5):2629–2634.
97. Johnson LL, Sayles PC. Deficient humoral responses underlie susceptibility to *Toxoplasma gondii* in CD4-deficient mice. *Infect Immun.* 2002;70(1):185–191.
98. Sibley LD, Mordue DG, Su C, Robben PM, Howe DK. Genetic approaches to studying virulence and pathogenesis in *Toxoplasma gondii*. *Philos Trans R Soc Lond B Biol Sci.* 2002;357(1417):81–88.
99. Denkers EY, Butcher BA, Del Rio L, Bannoun S. Neutrophils, dendritic cells and *Toxoplasma*. *Int J Parasitol.* 2004;34(3):411–421.
100. Gazzinelli R, Xu Y, Hieny S, Cheever A, Sher A. Simultaneous depletion of CD4+ and CD8+ T lymphocytes is required to reactivate chronic infection with *Toxoplasma gondii*. *J Immunol.* 1992;149(1):175–180.
101. Johnson LL, Gibson GW, Sayles PC. CR3-dependent resistance to acute *Toxoplasma gondii* infection in mice. *Infect Immun.* 1996;64(6):1998–2003.
102. Alexander J, Hunter CA. Immunoregulation during toxoplasmosis. *Chem Immunol.* 1998;70:81–102.
103. Jungi TW, Adler H, Adler B, Thony M, Krampe M, Peterhans E. Inducible nitric oxide synthase of macrophages. Present knowledge and evidence for species-specific regulation. *Vet Immunol Immunopathol.* 1996;54(1–4):323–330.
104. Hernandez-Mendoza L, Molinari JL, Garrido E, et al. The implantation of *Taenia solium* metacystodes in mice induces down-modulation of T cell proliferation and cytokine production. *Parasitol Res.* 2005;95(4):256–265.
105. Kaneko Y, Takashima Y, Xuaun X, et al. Natural IgM antibodies in sera from various animals but not the cat kill *Toxoplasma gondii* by activating the classical complement pathway. *Parasitology.* 2004;128 Pt 2:123–129.
106. Bailey M, Christoforidou Z, Lewis MC. The evolutionary basis for differences between the immune systems of man, mouse, pig and ruminants. *Vet Immunol Immunopathol.* 2013;152(1–2):13–19.
107. Zulpo DL, Headley SA, Biazzone L, et al. Oocyst shedding in cats vaccinated by the nasal and rectal routes with crude rhoptry proteins of *Toxoplasma gondii*. *Exp Parasitol.* 2012;131(2):223–230.
108. Machado AV, Caetano BC, Barbosa RP, et al. Prime and boost immunization with influenza and adenovirus encoding the *Toxoplasma gondii* surface antigen 2 (SAG2) induces strong protective immunity. *Vaccine.* 2010;28(18):3247–3256.
109. Bourguin I, Chardes T, Bout D. Oral immunization with *Toxoplasma gondii* antigens in association with cholera toxin induces enhanced protective and cell-mediated immunity in C57BL/6 mice. *Infect Immun.* 1993;61(5):2082–2088.
110. Crawford J, Lamb E, Wasmuth J, Grujic O, Grigg ME, Boulanger MJ. Structural and functional characterization of Sporozoite: a SAG2-related surface antigen from *Toxoplasma gondii*. *J Biol Chem.* 2010;285(16):12063–12070.
111. Burrells A, Bartley PM, Zimmer IA, et al. Evidence of the three main clonal *Toxoplasma gondii* lineages from wild mammalian carnivores in the UK. *Parasitology.* 2013;140(14):1768–1776.
112. Havelaar AH, Kemmeren JM, Kortbeek LM. Disease burden of congenital toxoplasmosis. *Clin Infect Dis.* 2007;44(11):1467–1474.
113. Falcon J, Freyre A. *Toxoplasma gondii*: prototype immunization of lambs against formation of muscle and brain cysts. *Vet Parasitol.* 2009;166(1–2):15–20.
114. Hiszczynska-Sawicka E, Li H, Xu JB, et al. Comparison of immune response in sheep immunized with DNA vaccine encoding *Toxoplasma gondii* GRA7 antigen in different adjuvant formulations. *Exp Parasitol.* 2010;124(4):365–372.
115. Hiszczynska-Sawicka E, Akhtar M, Kay GW, et al. The immune responses of sheep after DNA immunization with *Toxoplasma gondii* MAG1 antigen-with and without co-expression of ovine interleukin 6. *Vet Immunol Immunopathol.* 2010;136(3–4):324–329.
116. Hiszczynska-Sawicka E, Li H, Xu JB, et al. Modulation of immune response to *Toxoplasma gondii* in sheep by immunization with a DNA vaccine encoding ROP1 antigen as a fusion protein with ovine CD154. *Vet Parasitol.* 2011;183(1–2):72–78.
117. Hiszczynska-Sawicka E, Li H, Boyu Xu J, et al. Induction of immune responses in sheep by vaccination with liposome-entrapped DNA complexes encoding *Toxoplasma gondii* MIC3 gene. *Pol J Vet Sci.* 2012;15(1):3–9.
118. Mevelec MN, Ducournau C, Bassuny Ismael A, et al. Mic1-3 knockout *Toxoplasma gondii* is a good candidate for a vaccine against T. gondii-induced abortion in sheep. *Vet Res.* 2010;41(4):49.
119. Dubey JP. Prevention of abortion and neonatal death due to toxoplasmosis by vaccination of goats with the nonpathogenic coccidium *hammondia hammondi*. *Am J Vet Res.* 1981;42(12):2155–2157.
120. Dubey JP. Protective immunity against clinical toxoplasmosis in dairy goats vaccinated with *Hammondia hammondi* and *Hammondia heydorni*. *Am J Vet Res.* 1981;42(12):2068–2070.
121. Chartier C, Mallereau MP. [Efficacité vaccinale de la souche S48 de *Toxoplasma gondii* vis-à-vis d'une infection expérimentale chez le chevre]. *Ann Méd Vét.* 2001;145:202–209. French.
122. Dubey JP, Miller S, Desmonts G, Thulliez P, Anderson WR. *Toxoplasma gondii*-induced abortion in dairy goats. *J Am Vet Med Assoc.* 1986;188(2):159–162.
123. Dubey JP. Persistence of encysted *Toxoplasma gondii* in caprine livers and public health significance of toxoplasmosis in goats. *J Am Vet Med Assoc.* 1980;177(12):1203–1207.
124. Chiari CA, Neves DP. Toxoplasmose humana adquirida através da ingestão de leite de cabra [Human toxoplasmosis acquired through ingestion of goat milk]. *Memorias do Instituto Oswaldo Cruz.* 1984;79(3):337–340. Portuguese.
125. Vitor RWA, Pinto JB, Chiari CA. Eliminação de *Toxoplasma gondii* através de urina, saliva e leite de caprinos experimentalmente infectados [Elimination of *Toxoplasma gondii* through urine, saliva and milk from experimentally infected goats]. *Arq Brasil Med Vet e Zoot.* 1991;42(2):147–154. Portuguese.
126. Dubey JP. Toxoplasmosis in pigs – the last 20 years. *Vet Parasitol.* 2009;164(2–4):89–103.
127. Li X, Wang Y, Yu F, Li T, Zhang D. An outbreak of lethal toxoplasmosis in pigs in the Gansu province of China. *J Vet Diagn Invest.* 2010;22(3):442–444.
128. Dubey JP. Long-term persistence of *Toxoplasma gondii* in tissues of pigs inoculated with T gondii oocysts and effect of freezing on viability of tissue cysts in pork. *Am J Vet Res.* 1988;49(6):910–913.
129. Verhelst D, De Craeye S, Dorny P, et al. IFN-gamma expression and infectivity of *Toxoplasma* infected tissues are associated with an antibody response against GRA7 in experimentally infected pigs. *Vet Parasitol.* 2011;179(1–3):14–21.
130. da Cunha IA, Zulpo DL, Bogado AL, et al. Humoral and cellular immune responses in pigs immunized intranasally with crude rhoptry proteins of *Toxoplasma gondii* plus Quil-A. *Vet Parasitol.* 2012;186(3–4):216–221.
131. Wang Y, Zhang D, Wang G, Yin H, Wang M. Immunization with excreted-secreted antigens reduces tissue cyst formation in pigs. *Parasitol Res.* 2013;112(11):3835–3842.
132. Dubey JP, Lappin MR, Thulliez P. Long-term antibody responses of cats fed *Toxoplasma gondii* tissue cysts. *J Parasitol.* 1995;81(6):887–893.

133. Frenkel JK, Pfefferkorn ER, Smith DD, Fishback JL. Prospective vaccine prepared from a new mutant of *Toxoplasma gondii* for use in cats. *Am J Vet Res*. 1991;52(5):759–763.
134. Freyre A, Choromanski L, Fishback JL, Popiel I. Immunization of cats with tissue cysts, bradyzoites, and tachyzoites of the T-263 strain of *Toxoplasma gondii*. *J Parasitol*. 1993;79(5):716–719.
135. Mateus-Pinilla NE, Dubey JP, Choromanski L, Weigel RM. A field trial of the effectiveness of a feline *Toxoplasma gondii* vaccine in reducing *T. gondii* exposure for swine. *J Parasitol*. 1999;85(5):855–860.
136. Omata Y, Aihara Y, Kanda M, Saito A, Igarashi I, Suzuki N. *Toxoplasma gondii*: experimental infection in cats vaccinated with 60Co-irradiated tachyzoites. *Vet Parasitol*. 1996;65(3–4):173–183.
137. Mishima M, Xuan X, Yokoyama N, et al. Recombinant feline herpesvirus type 1 expressing *Toxoplasma gondii* ROP2 antigen inducible protective immunity in cats. *Parasitol Res*. 2002;88(2):144–149.
138. Williams DM, Grumet FC, Remington JS. Genetic control of murine resistance to *Toxoplasma gondii*. *Infect Immun*. 1978;19(2):416–420.
139. Suzuki Y, Orellana MA, Wong SY, Conley FK, Remington JS. Susceptibility to chronic infection with *Toxoplasma gondii* does not correlate with susceptibility to acute infection in mice. *Infect Immun*. 1993;61(6):2284–2288.
140. Waterston RH, Lindblad-Toh K, Birney E, et al. Initial sequencing and comparative analysis of the mouse genome. *Nature*. 2002;420(6915):520–562.
141. Mestas J, Hughes CC. Of mice and not men: differences between mouse and human immunology. *J Immunol*. 2004;172(5):2731–2738.
142. Gibbons DL, Spencer J. Mouse and human intestinal immunity: same ballpark, different players; different rules, same score. *Mucosal Immunol*. 2011;4(2):148–157.
143. Garweg JG, de Kozak Y, Goldenberg B, Boehnke M. Anti-retinal autoantibodies in experimental ocular and systemic toxoplasmosis. *Graefes Arch Clin Exp Ophthalmol*. 2010;248(4):573–584.
144. Freyre A, Araujo FA, Fialho CG, Bigatti LE, Falcon JD. Protection in a hamster model of congenital toxoplasmosis. *Vet Parasitol*. 2012;183(3–4):359–363.
145. Gormley PD, Pavesio CE, Minnassian D, Lightman S. Effects of drug therapy on *Toxoplasma* cysts in an animal model of acute and chronic disease. *Invest Ophthalmol Vis Sci*. 1998;39(7):1171–1175.
146. Esteban-Redondo I, Innes EA. Detection of *Toxoplasma gondii* in tissues of sheep orally challenged with different doses of oocysts. *Int J Parasitol*. 1998;28(9):1459–1466.
147. Benavides J, Maley S, Pang Y, et al. Development of lesions and tissue distribution of parasite in lambs orally infected with sporulated oocysts of *Toxoplasma gondii*. *Vet Parasitol*. 2011;179(1–3):209–215.
148. Garcia JL, Gennari SM, Navarro IT, et al. Partial protection against tissue cysts formation in pigs vaccinated with crude rhoptry proteins of *Toxoplasma gondii*. *Vet Parasitol*. 2005;129(3–4):209–217.
149. Bugni FM, Da Cunha IA, De Araujo MA, et al. [Action of beta-glucan in pigs experimentally infected with *Toxoplasma gondii* tachyzoites]. *Rev Bras Parasitol Vet*. 2008;17 Suppl 1:249–259. Portuguese.
150. Havelaar AH, van Rosse F, Bucura C, et al. Prioritizing emerging zoonoses in the Netherlands. *PLoS One*. 2010;5(11):e13965.
151. Moeller RB Jr. Causes of caprine abortion: diagnostic assessment of 211 cases (1991–1998). *J Vet Diagn Invest*. 2001;13(3):265–270.
152. Silva Filho MdF, Erzinger E, Cunha IAL, et al. *Toxoplasma gondii*: abortion outbreak in a goatherd from Southern Brazil. *Semina: Ciências Agrárias, Londrina*. 2008;29(4):887–894.
153. Lu F, Huang S, Kasper LH. The temperature-sensitive mutants of *Toxoplasma gondii* and ocular toxoplasmosis. *Vaccine*. 2009;27(4):573–580.
154. Martinez-Gomez F, Garcia-Gonzalez LF, Mondragon-Flores R, Bautista-Garfias CR. Protection against *Toxoplasma gondii* brain cyst formation in mice immunized with *Toxoplasma gondii* cytoskeleton proteins and *Lactobacillus casei* as adjuvant. *Vet Parasitol*. 2009;160(3–4):311–315.
155. Beauvillain C, Juste MO, Dion S, Pierre J, Dimier-Poisson I. Exosomes are an effective vaccine against congenital toxoplasmosis in mice. *Vaccine*. 2009;27(11):1750–1757.
156. Wang H, He S, Yao Y, et al. *Toxoplasma gondii*: protective effect of an intranasal SAG1 and MIC4 DNA vaccine in mice. *Exp Parasitol*. 2009;122(3):226–232.
157. Moire N, Dion S, Lebrun M, Dubremetz JF, Dimier-Poisson I. Mic1-3KO tachyzoite a live attenuated vaccine candidate against toxoplasmosis derived from a type I strain shows features of type II strain. *Exp Parasitol*. 2009;123(2):111–117.
158. Dziadek B, Gatkowska J, Brzostek A, Dziadek J, Dzitko K, Dlugonska H. *Toxoplasma gondii*: the immunogenic and protective efficacy of recombinant ROP2 and ROP4 rhoptry proteins in murine experimental toxoplasmosis. *Exp Parasitol*. 2009;123(1):81–89.
159. Jordan KA, Wilson EH, Tait ED, et al. Kinetics and phenotype of vaccine-induced CD8+ T cell responses to *Toxoplasma gondii*. *Infect Immun*. 2009;77(9):3894–3901.
160. Qu D, Yu H, Wang S, Cai W, Du A. Induction of protective immunity by multiantigenic DNA vaccine delivered in attenuated *Salmonella typhimurium* against *Toxoplasma gondii* infection in mice. *Vet Parasitol*. 2009;166(3–4):220–227.
161. Gigley JP, Fox BA, Bzik DJ. Long-term immunity to lethal acute or chronic type II *Toxoplasma gondii* infection is effectively induced in genetically susceptible C57BL/6 mice by immunization with an attenuated type I vaccine strain. *Infect Immun*. 2009;77(12):5380–5388.
162. Fox BA, Bzik DJ. Avirulent uracil auxotrophs based on disruption of orotidine-5'-monophosphate decarboxylase elicit protective immunity to *Toxoplasma gondii*. *Infect Immun*. 2010;78(9):3744–3752.
163. Laguia-Becher M, Martin V, Kraemer M, et al. Effect of codon optimization and subcellular targeting on *Toxoplasma gondii* antigen SAG1 expression in tobacco leaves to use in subcutaneous and oral immunization in mice. *BMC Biotechnol*. 2010;10:52.
164. Dziadek B, Gatkowska J, Brzostek A, et al. Evaluation of three recombinant multi-antigenic vaccines composed of surface and secretory antigens of *Toxoplasma gondii* in murine models of experimental toxoplasmosis. *Vaccine*. 2011;29(4):821–830.
165. Yuan ZG, Zhang XX, He XH, et al. Protective immunity induced by *Toxoplasma gondii* rhoptry protein 16 against toxoplasmosis in mice. *Clin Vaccine Immunol*. 2011;18(1):119–124.
166. Makino M, Uemura N, Moroda M, et al. Innate immunity in DNA vaccine with *Toxoplasma gondii*-heat shock protein 70 gene that induces DC activation and Th1 polarization. *Vaccine*. 2011;29(10):1899–1905.
167. Mendes EA, Caetano BC, Penido ML, Bruna-Romero O, Gazzinelli RT. MyD88-dependent protective immunity elicited by adenovirus 5 expressing the surface antigen 1 from *Toxoplasma gondii* is mediated by CD8(+) T lymphocytes. *Vaccine*. 2011;29(27):4476–4484.
168. Sanchez VR, Pitkowski MN, Fernandez Cuppari AV, et al. Combination of CpG-oligodeoxynucleotides with recombinant ROP2 or GRA4 proteins induces protective immunity against *Toxoplasma gondii* infection. *Exp Parasitol*. 2011;128(4):448–453.
169. Rashid I, Hedhli D, Moire N, et al. Immunological responses induced by a DNA vaccine expressing RON4 and by immunogenic recombinant protein RON4 failed to protect mice against chronic toxoplasmosis. *Vaccine*. 2011;29(48):8838–8846.
170. Yuan ZG, Zhang XX, Lin RQ, et al. Protective effect against toxoplasmosis in mice induced by DNA immunization with gene encoding *Toxoplasma gondii* ROP18. *Vaccine*. 2011;29(38):6614–6619.
171. Wang PY, Yuan ZG, Petersen E, et al. Protective efficacy of a *Toxoplasma gondii* rhoptry protein 13 plasmid DNA vaccine in mice. *Clin Vaccine Immunol*. 2012;19(12):1916–1920.
172. Cui X, Lei T, Yang D, Hao P, Li B, Liu Q. *Toxoplasma gondii* immune mapped protein-1 (TgIMP1) is a novel vaccine candidate against toxoplasmosis. *Vaccine*. 2012;30(13):2282–2287.
173. Li J, Han Q, Gong P, et al. *Toxoplasma gondii* rhomboid protein 1 (TgROM1) is a potential vaccine candidate against toxoplasmosis. *Vet Parasitol*. 2012;184(2–4):154–160.

174. Chuang SC, Ko JC, Chen CP, Du JT, Yang CD. Encapsulation of chimeric protein rSAG1/2 into poly(lactide-co-glycolide) microparticles induces long-term protective immunity against *Toxoplasma gondii* in mice. *Exp Parasitol*. 2013;134(4):430–437.
175. Yuan ZG, Ren D, Zhou DH, et al. Evaluation of protective effect of pVAX-TgMIC13 plasmid against acute and chronic *Toxoplasma gondii* infection in a murine model. *Vaccine*. 2013;31(31):3135–3139.
176. Zhao Y, Huang B, Huang S, et al. Evaluation of the adjuvant effect of pidotimod on the immune protection induced by UV-attenuated *Toxoplasma gondii* in mouse models. *Parasitol Res*. 2013;112(9):3151–3160.

Vaccine: Development and Therapy

Publish your work in this journal

Vaccine: Development and Therapy is an international, peer-reviewed, open access journal that spans the spectrum of vaccine design and development through to clinical applications. The journal is characterized by the rapid reporting of application notes, reviews, original research and clinical studies in all therapeutic areas. Clinical outcomes, patient safety,

Submit your manuscript here: <http://www.dovepress.com/vaccine-development-and-therapy-journal>

and programs for the development and effective, safe, and sustained use of vaccines will be a feature of the journal. The manuscript management system is completely online and includes a very quick and fair peer-review system. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Dovepress